lowRISC Collaborates with Industry Leaders to Create OpenTitan
lowRISC C.I.C., the open source silicon and tools collaborative engineering company, today announced that it has partnered with ETH Zürich, Google, G+D Mobile Security, Nuvoton Technology and Western Digital in support of OpenTitan, an open source hardware root of trust (RoT) reference design and integration guidelines that enable chip producers and platform providers to build transparently implemented, high-quality hardware RoT chips tailored for data center servers and other devices.
Security begins with infrastructure, and OpenTitan will help ensure root of trust in hardware, transparently implemented, at the foundation for a multitude of devices such as server motherboards, network cards, routers and IoT. Adopters of this framework can inspect and contribute to OpenTitan’s register-transfer level (RTL) design, firmware, and documentation, helping to build more transparent, trustworthy hardware RoT chips for everyone.
OpenTitan is stewarded by lowRISC, which provides a neutral home for collaborative engineering to develop and maintain open source silicon designs and tools for the long term. As with open source software, open silicon provides a deep level of transparency and therefore auditability, as well as enabling innovation. Shared open infrastructure technology permits focus on product differentiation, with shared costs and substantially reduced overall risk.
The Ibex RISC-V processor core, which was originally developed by ETH Zürich as zero-riscy and contributed to lowRISC earlier this year, forms a key component for OpenTitan. lowRISC is committed to raising the bar for quality in open silicon via a methodical approach that combines the development and use of best practices and coding standards, with rigorous testing and verification.
Key benefits of OpenTitan for chip manufacturers and platform providers include:
- Transparent: Adopters can inspect and contribute to OpenTitan’s design, firmware, and documentation, helping to build more transparent, trustworthy hardware RoT chips that benefit everyone.
- High-quality: OpenTitan’s goal is to build and maintain a high-quality and logically secure RTL design, firmware, and documentation. The project is staffed by expert engineers focused on rigorous design validation and technical documentation, all based on key learnings from designing Google’s Titan chips.
- Flexible: Adopters can increase their total addressable market and reduce costs by using a single platform-agnostic hardware RoT design that can be integrated in data center servers, peripherals, and any other hardware platforms.
“We believe collaboratively developed open source silicon designs provide the flexible, cost effective base needed for future generations of secure hardware products,” said Alex Bradbury, lowRISC CTO. “The lowRISC not-for-profit structure combined with full stack engineering capabilities in-house, enables us to manage high quality projects like OpenTitan, and we look forward to developing this partnership and new ones in the future.”
“At lowRISC, our mission is to establish a vibrant ecosystem around open silicon designs and to help lower the barrier to producing custom chips,” said Gavin Ferris, lowRISC CIC board member. “Creating an ecosystem of like-minded organizations focused on the goal of improving transparency around chips helps increase trust in the overall security of the infrastructure on which software runs. With OpenTitan, enterprise organizations and consumers alike will benefit from services built on a more secure infrastructure that is anchored in transparently implemented OpenTitan chips.”
“Customers are asked to put faith in proprietary hardware RoT chips for their mission-critical systems without the ability to fully understand, inspect and therefore trust them,” said Dominic Rizzo, OpenTitan Lead at Google and lowRISC’s OpenTitan Project Director. “By creating OpenTitan with the broader hardware and academic community, we can leverage the experience and security principles used to create Google’s own Titan chips to make hardware RoT designs more transparent, inspectable, and accessible to the rest of the industry. Security should never be built on opacity.”
Collaboration is fundamental to open silicon and at the core of everything that lowRISC does, bringing to projects a deep understanding of open source licensing, contributor models and community building, and providing a uniquely positioned engineering capability.
About lowRISC
lowRISC C.I.C. is a not-for-profit company that aims to demonstrate, promote and support the use of open-source hardware - bringing the benefits of open-source to the hardware world. We are producing high-quality, security-focused, open, and flexible IP. Our expertise includes the LLVM Compiler, novel hardware security extensions and RISC-V tools, hardware and processor design.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191105005089/en/
Contact information
Andrew Back
lowRISC
press@lowrisc.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
